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Abstract
Background: The Cord Pilot Trial compared alternative policies for timing of cord clamping at very preterm birth
at eight UK hospitals. Preterm birth can be rapid and unexpected, allowing little time for the usual consent process.
Therefore, in addition to the usual procedure for written consent, a two-stage pathway for consent for use when
birth was imminent was developed. The aims of this study were to explore clinicians’ views and experiences of
offering two consent pathways for recruitment to a randomised trial of timing of cord clamping at very preterm
birth.
Methods: This was a qualitative study using semi-structured interviews. Clinicians from eight hospitals in the
UK who had been involved in offering consent to the Cord Pilot Trial were invited to take part in an interview.
Clinicians were interviewed in person or by telephone. Interviews were analysed using inductive systematic
thematic analysis.
Results: Seventeen clinicians who had either offered usual written consent only (n = 6) or both the two-stage
pathway (with oral assent before the birth and written consent after the birth) and usual written consent (n = 11)
were interviewed. Six themes were identified: (1) team approach to offering participation; (2) consent form as a
record; (3) consent and participation as a continual process; (4) different consent pathways for different trials;
(5) balance between time, information, and understanding; and (6) validity of consent. Overall, clinicians were
supportive of the two-stage consent pathway. Some clinicians felt that in time-critical situations oral assent
presented an advantage over the usual written consent as they provided information on a “need to know” basis.
However, there was some concern about how much information should be given for oral assent, and how this
is understood by women when birth is imminent.
Conclusions: The two-stage pathway for consent developed for use in the Cord Pilot Trial when birth was
imminent was acceptable to clinicians for comparable low-risk studies, although some concerns were raised
about the practicalities of obtaining oral assent.
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Keywords: Clinical trials, Ethics, Consent, Oral assent, Preterm birth
* Correspondence: A.Sawyer@brighton.ac.uk
2Centre for Health Research, School of Health Sciences, University of
Brighton, Falmer BN1 9PH, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chhoa et al. Trials  (2017) 18:196 
DOI 10.1186/s13063-017-1940-5
Background
Recruitment to trials when very preterm birth (before
32 weeks gestation) is imminent requires approaching
women and their partners at a particularly difficult and
stressful time, often with limited time available for them to
make an informed decision. This raises challenges for
obtaining valid informed consent, both in terms of the
practicalities of giving detailed information in a short period
of time [1, 2] and in terms of the capacity of parents to
absorb and understand the information and to make a vol-
untary decision [3]. Nevertheless, parents want the oppor-
tunity to participate (or allow their infant to participate) in
perinatal research and value their role as decision-makers
[1, 3–5]. If strategies for offering rapid consent are not de-
veloped, women who are at highest risk would be excluded
from intrapartum trials, and trials of emergency perinatal
or neonatal care would not be possible.
The Cord Pilot Trial compared alternative policies for
timing of cord clamping at very preterm birth [6] at
eight UK sites. The two arms of the Cord Pilot Trial
were: (1) immediate cord clamping, which meant clamp-
ing the cord within 20 seconds; and (2) deferred cord
clamping, which meant clamping the cord after at least
2 minutes. For births with cord clamping after at least
2 minutes, initial neonatal care was at the bedside. In
some cases preterm birth may not happen suddenly.
However, in most cases, very preterm birth can be rapid
and unexpected, allowing little time for the usual con-
sent process. Therefore a two-stage pathway for consent
was developed for use when birth was imminent [7].
The aim was to ensure women and their babies at high
risk, who had largely been excluded from previous trials,
had the opportunity to participate. This two-stage path-
way involved giving a brief description of the trial and
offering the woman participation [7]; if she agreed to
participate she was randomised and then approached
after the birth to give more detailed information and of-
fered written consent for participation in follow up. Of
the 261 women randomised, 69 (26%) were recruited fol-
lowing oral assent. None of the women recruited via the
two stage-consent pathway who gave oral assent went
on to refuse follow up at the written consent stage. The
two-stage pathway was developed in discussion with,
and was endorsed by, parent representatives from Bliss,
the special care baby charity, and the National Child-
birth Trust. It is also in line with guidance on valid con-
sent for research while in labour [8]. The aim of this
study was to assess clinicians’ views and experiences of
offering these two consent pathways. Women’s views
and experiences are reported elsewhere (Sawyer, Chhoa,
Ayers, Pushpa-Rajah, Duley: Women’s views and experi-
ences of two alternative consent pathways for participa-
tion in a preterm intrapartum trial: a qualitative study,
submitted).
Methods
Participants and procedure
Principal Investigators at the eight sites were contacted
between September and December 2014 and asked to
provide a list of clinicians who had been involved in offer-
ing consent to the Cord Pilot Trial and were willing to be
interviewed. Information about the study and an invitation
to participate was sent by email to each clinician. The cli-
nician’s positive reply to this email was considered as their
agreement to participate in the study. They were then
contacted and an interview date arranged.
The interview schedule (Additional file 1) consisted
of open-ended questions, which were used to explore
clinicians’ views and experiences of inviting women to
take part in the trial [5]. Probes were used to explore
responses in more depth. Interviews were carried out
by a female research assistant (CC) trained in qualita-
tive methods (see Additional file 2 for reporting guide-
lines for qualitative studies). The interviewer would
introduce herself and explain the purpose of the re-
search. Interviews were conducted either in a private
hospital room or by telephone, and lasted approxi-
mately 20–30 minutes. No one was present apart from
the interviewer. Interviews were audio-recorded and
transcribed, with all identifying information removed.
Data collection ended when data saturation had been
achieved (i.e. no new insights were observed).
Data analysis
Qualitative analysis of the transcripts used inductive the-
matic analysis to identify, describe and analyse themes and
patterns within the data [9]. Thematic analysis was used to
inductively (from the data) analyse the interviews. After
transcripts were read and re-read for data familiarisation,
interviews were coded to generate an initial pool of codes
(AS). Codes were then collated into potential themes.
Themes were reviewed by three authors (AS, CC and SA)
in relation to the generated pool of codes and the entire
data set. Finally, definitions and names were generated for
each theme. NVivo Version 10 software (QSR International
Pty Ltd.) was used to manage codes and themes. For this
report, direct quotes are coded (participant number; job
role; type of consent) to ensure anonymity.
Results
Invitations to be interviewed were sent to 20 clinicians,
and 17 clinicians from 7 hospitals responded: 5 consultant
neonatologists, 3 neonatal or paediatric registrars, 5 neo-
natal nurses, and 4 midwives. Eleven clinicians (65%), in-
cluding all the consultants and registrars, had offered
women both the two-stage pathway and usual written
consent. Six (35%) had offered women standard written
consent only, and none had offered the two-stage pathway
only.
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Six major themes were identified in clinicians’ experi-
ences of offering the two consent pathways: (1) team
approach to offering participation; (2) consent form as a
record; (3) consent and participation as a continual
process; (4) different consent pathways for different trials;
(5) balance between time, information, and understanding;
and (6) validity of consent. Differences were explored be-
tween the professions; however, as there were no overall
differences between professional groups (i.e. doctor, nurse,
midwife) regarding the content of the themes, the results
are presented for the whole sample.
Team approach to offering participation
Over half of the clinicians discussed the importance of a
team approach to inviting women to participate in the
trial, regardless of which consent pathway was used.
Some clinicians mentioned that they used a team ap-
proach to explain the trial to women and invite consent.
For example, one neonatologist discussed that both he
and the research nurse approached women together and
then one of them would follow-up:
I think there’s a real advantage in having me and my
research nurse work quite closely together. We quite
often make a joint approach to somebody and then I
leave it with [research nurse] to follow up or indeed
the other way around. (16; Consultant Neonatologist;
oral and written consent)
Moreover, some clinicians felt that this approach had
the advantage of “covering all bases” with respect to pro-
viding potential participants with information: “having the
same person always delivering the same thing often
there’ll be blind spots or ways of approaching that doesn’t
work with other people” (1; Consultant Neonatologist;
oral and written consent). The team approach was also
seen as a more time-efficient method of offering consent
for busy clinicians:
When you’re a busy clinician that does take my time.
In [name of hospital] we’re very lucky in that in the
daytime we have a lot of research staff who take
consent, so they’re brilliant. If we’ve approached a
woman during the antenatal counselling giving them
a leaflet, then that will then be backed up by a
research nurse going to them and taking their
consent the following day. And I think that system
works really, really well. Written consent is generally
not a problem, the only con to it is the time. (8;
Neonatal Registrar; oral and written consent)
One clinician noted that it was also important to ask
the opinions of other staff about whether it was appro-
priate to approach a woman: “I did ask the midwives if it
was reasonable to make an approach” (16; Consultant
Neonatologist; oral and written consent). Some clini-
cians also thought that the most appropriate person to
initially provide information about the study was one of
the neonatal staff as part of their antenatal counselling
and that this should be embedded in the “normal care of
ladies having preterm babies” (9; Research Midwife; writ-
ten consent).
I think the consent process, particularly for Cord, is
quite often intertwined with antenatal counselling. So
if you’re about to have a preterm baby what will often
happen is someone will come to talk to you about
prematurity, preterm babies, what they’re going to do
during delivery, what’s likely to happen in the next
few hours and subsequently. And those conversations
overlap a little bit with the Cord trial consent, because
some of the conversations are about what they’re
going to do when your baby’s born. So it can be quite
difficult to separate those out, so if you had someone
who is just doing Cord consent but wasn’t involved in
the management of premature babies that would
potentially feel a bit artificial. (7; Consultant
Neonatologist; oral and written consent).
The importance of regular multidisciplinary training for
offering participation in the trial was also commented
upon by clinicians. This was highlighted as particularly
important for the two-stage consent pathway, when there
is often little time available and opportunities to offer oral
assent are lost if no trained clinicians are available. One
difficulty raised by some clinicians was the rotation of
registrars, and the need to ensure new staff members were
trained in offering consent was highlighted.
Consent form as a record
Seven clinicians discussed the issue of whether the
signed consent form is a record of the consent process
or a legal document to prove consent was given. One of
these seven clinicians highlighted that a tension existed
between the two perspectives:
So you know there’s a tension between the two sort
of approaches, is this a water-tight document? Have
you mentioned everything possible that you need to
mention? Is it comprehensive, detailed enough to
evidence the consent process? And then the other
approach that says that this is merely a record of
something. (1; Consultant Neonatologist; oral and
written consent)
Of the clinicians who discussed this, most were con-
cerned that at the point of oral assent there is a not a
clear record of the assent process, as the women do not
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have to sign anything. One clinician raised the concern
that “if you didn’t write it down, it didn’t happen” (16;
Consultant Neonatologist; oral and written consent).
While the women were not asked to sign a consent form
when offered participation via the oral assent pathway, cli-
nicians were asked to document this in women’s clinical
notes and to note whether or not they agreed to partici-
pate. Three clinicians pointed out this may be particularly
important if a participant was to question later whether or
not they did actually give oral assent.
I think it’s fundamental that you get informed written
consent because then it shows that the woman has
been able to make her own choice, she’s not being
forced to make a choice. And I suppose if she was to
turn around and say, well actually I didn’t consent to
this, but she’s signed so, you know, there’s proof that
she has. (3; Neonatal Nurse; written consent)
A number of clinicians recognised that if the consent
form is a record of agreement, then alternative ways of
recording oral assent could be explored to mitigate the
risk of not having enough evidence that it had taken
place. For example, using a microphone to record the
conversation, video record the conversation or ensure
that another staff member and or/family member is
there to witness the conversation. For situations where
time is critical, however, none of these may be practical.
Some clinicians raised the point that written consent
forms may be perceived as off-putting to potential par-
ticipants as they are “very legalistic”. Another clinician
thought that presenting parents with a document to sign
might pressure them to say yes. As such, it was felt that
oral assent may be “less threatening to women and also
that you’ve not got this piece of paper, oh here’s pen,
sign there, all that kind of stuff. That certainly as a
process is much easier” (1; Consultant Neonatologist;
oral and written consent). Similarly, a senior research
midwife (oral and written consent) noted that oral assent
may help a woman in labour make a more informed de-
cision as the focus is not on signing a piece of paper, but
rather on the conversation.
Finally, another issue raised about the two-stage con-
sent process was the risk of a lack of a standardised
approach:
There’s a sheet saying they’ve had verbal assent, or
they’ve given a verbal consent, rather, for the trial. But
what’s actually discussed within that could be variable
and may not be documented, so one person’s verbal
consent may be different form someone else’s. Actually
even the same person’s may be different according to
the situation and the time variable and other things like
language barriers. So the exact nature of what’s been
said isn’t really recorded in the same way it is with the
written information that’s being given out. (7;
Consultant Neonatologist; oral and written consent)
Consent and participation as a continual process
The process of consent for a randomised trial is not
simply the act of offering consent but also includes the
ongoing process of building rapport with participants and
families, giving information, answering questions whether
it is before or after written consent is obtained. The pre-
dominant view amongst clinicians was that consent to
participation in the trial should be a continual process
taking place over time rather than just at a single con-
tact: “Consenting isn’t a one-step process, it’s every
time you make contact you’re reaffirming that some-
body’s still happy for that to take place” (9; Research
Midwife; written consent only). In standard written
consent, for example, clinicians often reported meeting
with women and their partners and explaining the
study at least several times before they asked the
woman to make a decision about participation. Some
clinicians felt that one of the advantages of consent as a
more continual process was that speaking to families
on more than one occasion might help women under-
stand and retain the information about the trial. One
midwife (written consent) also felt that this repeated
contact with families helped develop a rapport between
them. The same midwife discussed how this extra time
with parents can be used to give general information
about preterm birth and mother-baby bonding:
The pros are that you’re going to be able to inform a
woman and have dialogue with the woman and get to
know them. So, for example, if I’ve gone back to see
them a few times on the ward, I’ve often done that
social call afterwards so that you build up a bit of a
rapport with them. (4; Research Midwife; written
consent only)
… if you get written consent and it’s not done in a
hurry like oral, loads of loads of opportunity to just
go and to chat and to talk about stabilisation and
to talk about the relationship between mother and
baby. (4; Research Midwife; written consent only)
Although recognised as an optimal method of offering
consent it was recognised by some clinicians that the
time spent with families in the consent process can be
particularly time-consuming.
I do find that it takes an awful long time, it’s not
news to spend an hour or more talking to them.
I have spent three hours with a family, just because
they’ve got so many questions and there’s so much
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else going on. Not all in one go but over a period
of a few days, it’s amounted to at least three hours’
time that you’ve spent within that consent process.
(11; Neonatal Nurse; oral and written consent)
One clinician thought that written informed consent is
more aligned with consent as a continual process com-
pared to oral assent:
It [consent] should be a process, an on-going process,
continuing to re-confirm engagement with the trial
and their willingness to continue. I think consent fits
better with that and I think it is certainly easier to
evidence that you have that process. (16; Consultant
Neonatologist; oral and written consent)
The notion of the continuity of the consent process was
also prevalent in clinicians’ discussions of oral assent.
Provision of information in the first stage of the two-stage
consent pathway is on a “need to know”’ basis and women
and their partners are given only the minimum informa-
tion necessary for participation. The majority of clinicians
who had used the two-stage pathway for consent thought
the minimum information necessary for oral assent were
randomisation, the intervention and its risks and the
women’s right to decline participation or withdraw from
the study.
I find that that with the women, all of the questions
that you get are all about the intervention, and
randomisation and safety. None of them asks
questions about follow up. So I think talking to
them about the randomisation is fine and I think
if you started to talk to them about all of the follow-
up and that kind of thing at that point, you know,
I don’t know how much interest they would take in
that. Obviously, when you go to them afterwards to
ask for consent, that’s when you talk about all that
kind of thing. (12; Neonatal Nurse; oral and written
consent)
Therefore, the majority of clinicians thought that the
written stage in the two-stage pathway was essential in
confirming their continuing consent, and in giving the
women further information with respect to follow up,
the use of their data, etc.
Well I think generally in any study you have to
remind people and make sure that they fully
understand, but also the specifics because if the
woman is in labour or delivery is threatened early
I still feel that they are not in the full frame of mind
to grasp everything that you’re saying. So being able
to come back when they are little bit more relaxed
hopefully and can take in more information and
not in pain, then yes it’s definitely important. Just
reconfirming understanding and that they still wish
to be part of the trial. (5; Neonatal Registrar; oral
and written consent)
I think it’s important to continue the- essentially
you’re starting a conversation with somebody who
might be in relatively advanced labour, so it’s about
checking understanding as much as anything. And
obviously we’re getting someone to sign the dotted
line and in doing so you’re kind of cover oneself and
getting permission to use information. So really it’s a
continuation of a consent conversation and that’s the
way it ought to be. (16; Consultant Neonatologist; oral
and written consent)
Different consent pathways for different trials
This theme describes how the two different types of con-
sent processes were viewed as more or less acceptable
depending on the type of intervention in the trial. The
consensus was that the usual written informed consent
process was the optimal form of consent, and should be
used wherever possible. Many clinicians thought that the
two-stage consent pathway would be appropriate for tri-
als where the intervention is low risk and/or non-
complex and thus more acceptable to participants. For
example, some clinicians thought that oral assent would
be useful in the Total Body Hypothermia (TOBY) trial
in which infants had to be randomised within 6 hours of
birth [10]. Most clinicians thought the two-stage consent
pathway was acceptable for the Cord Pilot Trial, which
was essentially viewed as evaluating a more physiological
approach than current standard care: “So certainly for a
trial like ours where it’s straightforward, then I think it’s
really very successful” (1; Consultant Neonatologist; oral
and written consent). In comparison, for trials with a
higher risk profile, such as certain pharmacological in-
terventions, the two-stage consent pathway was not
thought to be appropriate.
The two-stage consent pathway was also thought to be
appropriate for trials where a decision about participa-
tion needs to be made quickly, for example, emergency
interventions/treatment:
I think it depends on the nature of the trial. I don’t
think it should be the default option, I think it’s more
for emergency or time-critical situations. In that situ-
ation I think it’s a reasonable model. (7; Consultant
Neonatologist; oral and written consent).
In addition, most clinicians thought oral assent mini-
mised any unnecessary burden to a woman who might
already be in considerable distress. A further important
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advantage of having a two-stage consent pathway for
perinatal trials where there is limited time to make a
decision was that more women were offered the oppor-
tunity to participate in the trial:
I think it would be to capture more people, because
the nature of this particular trial is that many women
will come just before delivery and there will not be
time. If you’re waiting for the ideal time to get written
consent for everybody, for this particular trial, it may
not happen and you’ll have less people. (5; Neonatal
Registrar; oral and written consent)
… it means that you don’t miss patients that would
potentially- well, a third of our recruitment would be
missed if it hadn’t been there. Because there’s not any
risks to what we’re doing, then it would be a shame to
miss them if it’s something that they would have liked
to have been involved in. (11; Neonatal Nurse; oral
and written consent)
Giving more women the opportunity to participate
may therefore mean that the final sample is more gen-
eralisable, as the higher risk mothers and babies are
now included:
The pros are that you can get ladies when they’re
close to delivery and still get them into the trial.
I think that’s important because we want a good
comparison between the two groups. We want the
data that we get for them trial to be generalisable,
don’t want it to only be applicable to ladies who’ve
got plenty of time and you’re doing a section. We
want it to be important for babies who are being born
prematurely as well. (6; Consultant Neonatologist; oral
and written consent)
I think you have to pursue it definitely, because
otherwise you’re going to end up with different
patient groups and your trial is not going to be valid,
your outcome’s not going to be valid. (8; Neonatal
Registrar; oral and written consent)
Also, one clinician thought these women, who are
eligible but do not have much time, have the right to be
offered participation in the study:
And I think they have a right to be offered that and
make a decision if we can actually get the information
across in a reasonable way to them. (7; Consultant
Neonatologist; oral and written consent)
Thus, having both consent pathways available meant
that opportunities for recruitment to the trial are not lost
where there is limited time for standard written consent
procedures and with regards to the Cord Pilot Trial one
clinician said that written consent would not have been
good on its own.
Balance between time, information, and understanding
When offering participation in a trial there has to be a
balance between the time available and the amount of
information given. Oral assent was offered to women
when birth was imminent and there was limited time, so
many of the women were in labour, in pain or being pre-
pared for a caesarean section. Therefore, information
giving and offering consent is happening in an already
stressful context. One consultant neonatologist (oral and
written consent) mentioned that they often only have
time to give the headlines of what the study is about, but
also felt that less information was easier for women to
grasp in such situations:
… if it’s the headlines then they get their head around
a few salient points, then they’re more likely to take
that on board then be able to say yes or no, rather
than ‘actually there’s too much, I can’t actually think
about that now’. (7; Consultant Neonatologist; oral
and written consent)
Some clinicians were concerned about how much
women in those situations understood and absorbed
about the study:
But it is, you know, oral assent is questionable exactly
how much information can be given and how much
can they actually understand. (3; Research Midwife;
written consent only)
… but I must say it is a situation where they are
in labour, they are having the stress of having a
premature delivery, so you could always argue how
much of them are really, just like the woman I
mentioned who couldn’t make the decision. I think it’s
a difficult time to make a decision that you feel 100%
confident with because there are other things on your
mind. (5; Neonatal Registrar; oral and written consent)
Most of the clinicians described situations when a
woman agreed to the study but after birth had forgotten
details about the study or did not have a thorough
understanding of the trial, and that this applied to both
women who gave oral assent and those who gave stand-
ard written consent:
She was happy to take part and was consented and
randomised into of the trial into the deferred clamping,
but we did need to revisit that afterwards to go through
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things because although her partner had a reasonably
clear recollection, mum was really quite patchy on
things. (7; Consultant Neonatologist; oral and written
consent)
However, there was general consensus amongst clini-
cians that the time available varied greatly between
women and was just often a function of the situation. For
example, two clinicians mentioned that women labour dif-
ferently and this can affect their focus and understanding.
Also, the time available can vary significantly between
women when oral assent is offered:
I would think that varies so much in each situation.
I don’t think can be general about that, because, like
I say, some have seconds to make the decision and
some have ten minutes to make the decision, but I
think there’s a massive difference in that. (10; Research
Nurse; oral and written consent)
One clinician mentioned that for families with lower
levels of education, the two-stage consent pathway may
not be appropriate as there is often too little time to ensure
proper understanding of the trial and what participation
involves. It was also mentioned that it was really important,
when offering oral assent, that women were approached at
the right time and given the right amount of information.
As oral assent was being offered at a stressful time, giving
lots of information is not appropriate either, as one clin-
ician mentioned: “I think if you try to double the informa-
tion you might well half the recollection” (7; Consultant
Neonatologist; oral and written consent).
Validity of consent
Fourteen clinicians discussed the issue of validity of
women’s consent when offering participation using the
two-stage consent pathway. Several expressed concern
that in time-critical situations when birth is imminent and
women are stressed out and may be in pain, it is question-
able whether information about the trial is taken in:
I don’t think it’s as good as written consent lots of
time because I don’t think they take in as much
information. You could be in a situation where you
wonder really have they been properly informed,
because if you ask them they’ll say yes they know
what’s going on but if you ask afterwards the
recollection of what was said is hazy. More so for the
mums than the dads, but that’s understandable
because the mums are in labour. (7; Consultant
Neonatologist; oral and written consent)
The cons are how do you know that that woman who
is labour is taking in anything at all what you’re saying
to her and would she just agree to anything at that
point because she’d rather just get on with having her
baby than talking to you. (8; Neonatal Registrar; oral
and written consent)
In comparison, four clinicians commented that oral
assent might enhance the validity of consent in stressful
and difficult circumstances:
… where you’ve got a lady really isn’t in the right
frame of mind, she’ll just sign anything. Whereas if
you’re actually talking to her and asking her, I think
you’ve got more chance of her actually making an
informed decision. (9; Research Midwife; written
consent only)
Well, if they’re in pain I would be more tempted to go
for verbal in that situation rather than written. That’s
why I’d go for verbal. I think that’s the way I would
go, because it’s quick, you can have a quick overview
in between contractions rather than them having to
read. You know, so you can say “you can say no”. So I
think I would rather go down the road of verbal for
that one, and then get the retrospective written. (13;
Midwife; oral and written consent)
Several clinicians thought it would be a good idea if the
study information was made available to women as early
as possible. For example, information about the trial could
be given to all women during antenatal visits with com-
munity midwives. This would mean that eligible women
might have an understanding of the trial when they are
first approached about the study by a member of the re-
search team. This would be particularly beneficial for
time-critical situations where oral assent is offered.
Because I have been to one or two where I’ve sort of
mentioned the trial and they have said to me, oh I
think I’ve read about that. They just pick them up at
the maternity base where information leaflets are and
they’ve said to me, oh I have read something about
the Cord trial, which is good so they have a little bit
of an insight before they even start. (2; Neonatal
Nurse; written consent)
It would probably be a good idea if it wasn’t
something they are hearing for the first time and it
wouldn’t have sounded experimental to them if they
had seen some information about it. So I think that
would probably have made it more, maybe,
normalised it a bit more. (5; Neonatal Registrar; oral
and written consent)
Finally, one clinician thought that “truly informed con-
sent” only happens when the women have time to read
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the information sheet, ask questions, and have time to
think without feeling pressured.
Discussion
The aim of this study was to explore clinicians’ views
and experiences of using two consent pathways during a
trial of timing of cord clamping at very preterm birth.
Women’s views are reported elsewhere. Overall, the cli-
nicians in our study were supportive of the two-stage
consent pathway developed to allow women about to
give birth the opportunity to participate in this trial.
Some clinicians felt that in this situation oral assent
presented an advantage over the usual written consent
as they provided information on a “need to know”’ basis,
so only minimal information is provided about the study
at time of recruitment, with additional information and
discussion after the birth. There was some concern
about how much information should be given for oral
assent, and how this is understood by women when
birth is imminent. Others thought that this was a more
appropriate approach than putting a piece of paper with
lengthy detailed information and legalistic terms in front
of a woman when birth was imminent. Clinicians were
supportive of a two-stage consent pathway for similar
trials with low-risk intervention, but cautious about its
appropriateness for higher-risk trials.
Although the clinician completed an oral assent form,
the woman was not asked to sign anything at the time of
recruitment via the oral assent pathway. This was a con-
cern for some clinicians. Some women in our study said
they had forgotten that they agreed to the research,
though it is important to note that this was also evident in
women recruited using written consent. Documentation
from the participant themselves at time of assent may be
particularly important if a participant was to question later
whether or not they did actually give oral assent. Sugges-
tions for alternative ways of documenting that oral assent
have been offered, included audio or video-recording the
conversation, and ensuring that another family member is
present as a witness. However, these have practical limita-
tions as recording would also require consent and the
equipment to be rapidly available, and finding a family
member may take time. When birth is imminent or in
comparable situations, these would not be possible.
In this study, clinicians considered consent to be a con-
tinuous process, rather than a single contact, regardless of
which consent pathway was used. Some considered the
two-stage consent pathway offered an advantage, as oral
assent was followed up with more information and discus-
sion after the birth before the woman was asked for
written consent. Continuous consent is an approach
recommended by Allmark and Mason [10], where there is
initial agreement to participate but there is also continued
discussion and information after the treatment. A
qualitative study evaluating the effectiveness of continuous
consent reported that the validity of consent improved
when discussion continues after treatment. However, al-
though parents in the study were positive overall about
continuous consent some parents expressed concerns.
Specifically, they were worried about receiving informa-
tion at a later date which could have impacted their ori-
ginal decision [10]. There was agreement that regular
training for offering consent to the trial was important.
For the two-stage consent pathway, recruitment was
predominantly by CORD-trained clinical staff involved
in the patient’s direct care, such as doctors and mid-
wives, as research staff (e.g. research midwife or re-
search nurse) were unlikely to be available. If trained
clinical and research staff were not available, oral assent
could not be offered and so women were not offered
the opportunity to participate. Another concern expressed
by clinicians was that the information given for oral assent
might have been variable. One way to monitor variability
would be for clinicians to be provided with a structured
format for writing down their conversations for oral
assent.
The Cord Pilot Trial compared interventions during
birth, and recruitment to the trial was often when
women were in labour and/or when birth was imminent.
The clinicians in our study were concerned about how
much information is understood by women when birth
is imminent, particularly with intrapartum women who
may be in pain or having a consent conversation in be-
tween contractions. For this reason, some clinicians felt
that the two-stage consent pathway with only minimal
information about the trial provided at recruitment is
adequate, and a more appropriate approach than the
usual written consent process. Previous research has
found that parents agree with this, valuing information
about potential risks and benefits over details of the
study procedures [11, 12]. Women in our study who
were recruited when birth was imminent and there was
little time to make a decision also felt it was easier to
consider participation when clinicians provided minimal
and clear information about the trial. This suggests that
consent in time-critical situations could focus on infor-
mation that is relevant to the immediate situation, leav-
ing other issues such as discussion of follow up and
signing the consent form until after the birth. Moreover,
consent forms and signatures do not ensure informed
decision-making [13] and some clinicians in our study
agreed, pointing out that in an emergency or stressful
situation women may just sign the consent form in
order to get the researcher to go away. Indeed, previous
research suggests that parents may be more likely to en-
gage in a conversation about a study when the consent
process conversation is not focused around a consent
form [14] and clinicians in our study agreed with this.
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This has implications for the validity of consent. The
consent form is less important than communicating in-
formation in a manner that is effective and appropriate
given the situation, and for some situations oral assent
may provide the best approach for doing so.
Researchers have questioned the capacity of parents to
absorb and understand information and make a fully in-
formed decision in emergency situations [3] but women
and parents want the opportunity to participate and to
make their own decisions [5] and a great deal of import-
ance has been attached by codes of ethics to gaining
informed consent for medical research [15]. If the prob-
lem of rapid parental consent cannot be successfully ad-
dressed, there is a risk that some valuable research in
the areas of preterm birth and emergency perinatal care
will not be possible. The two-stage consent pathway
used in the Cord Pilot Trial is one strategy with poten-
tial to overcome some of the problems of gaining con-
sent for neonatal and perinatal research when there is
insufficient time for the usual single-stage informed con-
sent process. The importance of offering participation in
trials when time is critical is also reflected in the two-
stage consent pathway developed for the Cord Pilot Trial
being incorporated into the Royal College of Obstetri-
cians and Gynaecologists clinical governance advice [16].
The two-stage pathway could also be used in clinical
scenarios where standard written consent is difficult (e.g.
non-planned surgery where urgent medical intervention
is needed) and has potential to overcome challenges of
obtaining consent in the standard way for non-planned
urgent interventions.
However, recent systematic reviews of the literature
on consent in neonatal and perinatal research have
highlighted a significant gap in the empirical and theor-
etical literature of any detailed discussion of a process
of emergency assent followed later by full consent [5, 17].
Some concern has been raised that consent at the second
stage only provides permission to continue and cannot
provide retrospective consent. This is particularly relevant
to one-off interventions; although consent would still be
applicable to use of personal data for research and subse-
quent follow up. Therefore, considered theoretical and
empirical attention to this process is urgently needed,
where parents assent or refuse participation during the
emergency and later give full consent to continue partici-
pation and follow up.
Strengths and limitations
A recent review of ethics issues around consent in clinical
trials with preterm or sick neonates identified a significant
gap in the literature evaluating emergency assent [5]. This
is the first study to explore clinicians’ experiences of invit-
ing women to participate in a randomised trial using a
two-stage oral assent pathway, with initial oral assent
followed by written consent. The use of detailed qualita-
tive methods allowed an in-depth exploration of these ex-
periences and allows a comparison of the two consent
pathways. Clinical staff members with a range of clinical
backgrounds from seven of the eight UK hospitals who
participated in the Cord Pilot Trial were interviewed, sug-
gesting that the findings are representative of experiences
in this trial. Our results are based on a single trial, and
other factors may be more important, or less important,
in trials with different populations and different risk and
benefit profiles.
Conclusions
Improving access to emergency trials when time is critical
is important if we are to develop an appropriate evidence
base for these clinical problems. The two-stage consent
pathway developed for use in the Cord Pilot Trial when
birth was imminent was acceptable to clinicians for com-
parable low-risk studies, although some concerns were
raised about the practicalities of obtaining oral assent.
This is the first empirical study to evaluate a novel process
of seeking parental consent for neonatal and perinatal re-
search when there is insufficient time for the usual single-
stage informed consent process. The process requires fur-
ther development and evaluation including evaluating this
process in trials with different populations and different
risk and benefit profiles. Different ways of documenting
assent should also be explored to enable a record of the
process. However, the option of oral assent followed later
by full consent should be considered for similar trials
where the intervention is low risk and time is critical.
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